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We read with great interest the article by Haque and 
colleagues [1] in a recent issue of Arthritis Research & 
Th  erapy. Th   ey hypothesized that co-transduction of CD4+
T cells with both forkhead box P3 transcription factor 
(FoxP3) and Bcl-xL will gener  ate highly reactive regulatory 
T cells (Tregs) that can be used to prevent auto  immune 
disease. Th  e authors showed that the accu  mulation, 
persistence, and eﬃ     cient function of Tregs were 
attributable to the expression of Bcl-xL in CD4 Tregs.
Indications for a potential role of Bcl-xL in the 
development of functional Tregs were ﬁ  rst described by 
our group, and the results of studies supporting this 
notion were published in numerous journals (for exam-
ple, [2-5]). Because this information was not mentioned 
in the article by Haque and colleagues [1] and because 
the results presented in their article conﬁ  rm our previous 
studies [2-5], we think that it is important, scientiﬁ  cally 
and ethically, to acknowledge these data.
Our group has been studying systemic lupus erythe  ma-
tosus (SLE) and developed a tolerogenic peptide, namely 
hCDR1, shown to ameliorate manifestations of the 
disease through several mechanisms of action, including 
the induction of CD4 Tregs [2]. We showed that Bcl-xL 
was upregulated in CD4 Tregs of SLE-aﬀ  ected 
(NZBxNZW)F1 mice follow  ing treatment with the 
tolero  genic peptide [3]. Bcl-xL played a suppressive role 
in the tolerized mice, as it inhibited the activation of T 
and B cells, and mediated the downregulating eﬀ  ects of 
hCDR1 on the production of the pathogenic cytokines 
interferon-gamma and interleukin-10 and the upregu-
lating eﬀ  ects on the immunosuppressive cytokine trans-
forming growth factor-beta (TGF-β). Furthermore, CD4 
Tregs of the tolerized mice elicited the expression of Bcl-
xL in the eﬀ  ector CD4 cells, thus contributing to the 
amelioration of SLE manifestations [3]. Although CD8 
Tregs could not trigger the expression of Bcl-xL in 
eﬀ  ector CD4 cells, the former cells were essential for the 
optimal inhibitory function of CD4 Tregs [4]. Finally, we 
demonstrated that Bcl-xL played a role in inducing the 
regulatory/inhibitory molecules FoxP3, cytotoxic T 
lymphocyte antigen 4 (CTLA-4), and TGF-β and in 
repressing PD-1 (pro  grammed death 1) [5]. We showed 
that Bcl-xL also mediated the induction of CTLA-4 and 
TGF-β in eﬀ  ector CD4 cells by CD4 Tregs of the tolerized 
mice, thus explaining the inhibition of proliferation and 
the decreased activation of eﬀ  ector CD4 cells [5]. Th  ese 
newly described roles of Bcl-xL may provide a novel 
mechanism of induction of CD4 Tregs. All together, our 
data [2-5], supported by those presented by Haque and 
colleagues [1], suggest that immunomodulation of Bcl-xL 
expression in T cells might be valuable for controlling 
and treating diseases that are aﬀ  ected by CD4 Tregs.
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